otid Embolic Protection Using MicroNet) trial included 30 consecutive patients
from four centers in Germany and Poland. The 30-day
major adverse cardiac or cerebrovascular event risk was
0%. New silent ipsilateral ischemic lesions on diffusionweighted MRI at 48 hours occurred in 37.0% of patients.
Thirty-day diffusion-weighted MRI showed complete resolution of all but one periprocedural lesion and only one
new minor lesion in relation to the